Research &
Case Studies
Published Research Matters
BioSymetrics believes in data from beginning to end. This includes identifying opportunities to publish peer-reviewed research that validate our methods and discoveries. Here we also share pre-print and other types of research, given innovation sometimes moves faster than review cycles.
-
Broad Institute Machine Learning in Drug Discovery Symposium
-
Drivers of mortality in COVID ARDS depend on patient sub-type
-
MOA Miner Publication Case Study
-
Toronto Machine Learning Summit (TMLS) presentation – June 12-14, 2023
-
Poster Presentation – Muscular Dystrophy Association Clinical & Scientific Conference March 19 – 22, 2023
-
Poster Presentation – Society for Laboratory Automation and Screening (SLAS) 2023 International Conference and Exhibition
-
Discriminating Acute Respiratory Distress Syndrome from other forms of respiratory failure
-
Poster Presentation – American Epilepsy Society (AES) 2022
-
Phenotype-Driven Identification of Drug Targets For Post-COVID-19 Anosmia
-
Drivers of Mortality in COVID ARDS Depend on Patient Sub-Type
-
C reactive protein utilisation, a biomarker for early COVID-19 treatment
-
Paper - Using iterative Machine Learning (Contingent-AI) in a clinical setting
-
White Paper - Using AI to Discover Target and MOA Prediction Using HCI Screen
-
Poster Presentation - MIT AI in Drug Discovery Conference2020
-
MOA Analysis for Rare Cancer (Pre-Print - bioRxiv)
-
The Lancet Study on COVID-19 featuring BioSymetrics
Interested in Partnering?
We seek partners with a desire to transform drug discovery, to help advance our drug discovery programs or embark on new programs in cardiac, neurodegenerative and rare diseases.
We are highly collaborative experts in machine learning, data science and drug discovery. Let’s chat.